Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

Abstract Introduction Obesity contributes to inflammation and may decrease psoriasis treatment efficacy. We investigated whether obesity affects the efficacy and safety of tildrakizumab, an anti-interleukin-23 p19 antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis...

詳細記述

書誌詳細

主要な著者:	Howard L. Sofen, Ranga Gogineni, Tushar Nishandar, Jerry Bagel
フォーマット:	Artigo
言語:	Inglês
出版事項:	Adis, Springer Healthcare 2026-05-01
シリーズ:	Dermatology and Therapy
主題:	Plaque psoriasis Obesity Psoriasis Scalp Severity Index (PSSI) Investigator Global Assessment modified 2011 of the scalp (IGA mod 2011 [scalp]) score Scalp psoriasis Tildrakizumab
オンライン･アクセス:	https://doi.org/10.1007/s13555-026-01774-2
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!